Drugmaker Novartis filed a lawsuit May 29 against the state of Maryland over a new law that forbids manufacturers from “taking certain direct or indirect actions to limit or restrict the acquisition or delivery of a 340B drug.”
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
